0JXI.LSE Madrigal Pharmaceuticals Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2021.
Is 0JXI.LSE undervalued?
Graham numberThe Graham number of Madrigal Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Madrigal Pharmaceuticals Inc. fundamental analysis
No fundamental analysis for Madrigal Pharmaceuticals Inc. yet.
Madrigal Pharmaceuticals Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Full company profileMadrigal Pharmaceuticals Inc. financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Madrigal Pharmaceuticals Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|
| Cash Flow | |||||
| Operating Cash Flow | -22.3M | -25.5M | -41.6M | -158M | - |
| Capital Expenditure | 125K | 22.0K | 172K | 334K | 0.00 |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Madrigal Pharmaceuticals Inc. dividends
Madrigal Pharmaceuticals Inc. has not paid dividends in the last 8 fiscal years.
Who owns Madrigal Pharmaceuticals Inc.
- Insiders 5.83%
- Institutions 94.17%
- Public & others 0.00%
- Free float 13.7M
Madrigal Pharmaceuticals Inc. company profile
- Company name
- Madrigal Pharmaceuticals Inc.
- Ticker
- 0JXI.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 915
- Fiscal year end
- December
- Address
- 1001 Conshohocken State Road, West Conshohocken, PA, United States, 19428
- Phone
- 267 824 2827
- Website
- madrigalpharma.com
About Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals Inc. management
10- Mr. William J. SiboldCEO, President & Director · born 1966
- Dr. Rebecca A. Taub M.D.Founder, Senior Scientific & Medical Advisor and Director · born 1952
- Ms. Mardi C. DierExecutive VP & CFO · born 1964
- Ms. Shannon KelleyExecutive VP, Chief Legal Officer & Corporate Secretary · born 1975
- Ms. Carole HuntsmanExecutive VP & Chief Commercial Officer · born 1965
- Dr. David Soergel M.D.Executive VP & Chief Medical Officer · born 1968
- Mr. Mark UnderwoodExecutive Vice President of Business Planning & Operations
- Ms. Rita ThakkarSenior VP & Chief Accounting Officer · born 1974
- Mr. Ronald FilippoExecutive VP & Chief Information Officer
- Ms. Tina E. VenturaChief Investor Relations Officer